![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Avijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni & Jeffrey M Cochran. (2023) Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach. ClinicoEconomics and Outcomes Research 15, pages 375-386.
Read now
Read now
Benjamin Kearns, Katy Cooper, Anna Cantrell & Chloe Thomas. (2021) Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. Neuropsychiatric Disease and Treatment 17, pages 125-137.
Read now
Read now
Ilaria Cuomo, Georgios D Kotzalidis, Simone de Persis, Daria Piacentino, Filippo Perrini, Emanuela Amici & Sergio De Filippis. (2018) Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatric Disease and Treatment 14, pages 1645-1656.
Read now
Read now
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig & Leslie Citrome. (2018) Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research 10, pages 443-456.
Read now
Read now
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Pierre Chue & James Chue. (2016) A review of aripiprazole long-acting injection. Current Medical Research and Opinion 32:3, pages 441-452.
Read now
Read now
Thomas R. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe & Basil G. Bereza. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics 19:2, pages 121-130.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Articles from other publishers (11)
Vanessa Sanchez-Gistau, María José Moreno, Susana Gómez-Lus, Antoni Sicras-Mainar & Benedicto Crespo-Facorro. (2023) Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study. Frontiers in Psychiatry 14.
Crossref
Crossref
Marjanne A. Piena, Natalie Houwing, Carla W. Kraan, Xiaofeng Wang, Heidi Waters, Ruth A. Duffy, Suresh Mallikaarjun & Craig Bennison. (2021) An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics 40:1, pages 121-131.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2021) Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?. Clinical Psychopharmacology and Neuroscience 19:3, pages 434-448.
Crossref
Crossref
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Crossref
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney & Heidi Waters. (2018) Cost–effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. Journal of Comparative Effectiveness Research 7:7, pages 637-650.
Crossref
Crossref
S. Druais, A. Doutriaux, M. Cognet, A. Godet, C. Lançon, P. Levy, L. Samalin & P. Guillon. (2017) Comparaison des bénéfices médico-économiques des antipsychotiques dans la prise en charge de la schizophrénie en France. L'Encéphale 43:4, pages 311-320.
Crossref
Crossref
Leslie Citrome. (2017) Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?. CNS Spectrums 21:S1, pages 1-12.
Crossref
Crossref
Sylvain Druais, Agathe Doutriaux, Magali Cognet, Annabelle Godet, Christophe Lançon, Pierre Levy, Ludovic Samalin & Pascal Guillon. (2016) Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. PharmacoEconomics 34:4, pages 363-391.
Crossref
Crossref
Anne Karow, Monika Bullinger & Martin Lambert. 2016. Beyond Assessment of Quality of Life in Schizophrenia. Beyond Assessment of Quality of Life in Schizophrenia
123
144
.
Matt Shirley & Caroline M. Perry. (2014) Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. Drugs 74:10, pages 1097-1110.
Crossref
Crossref